Navigation Links
Avrio Receives Drug Manufacturing License and Medical Device Manufacturing License from the California Food and Drug Branch
Date:2/10/2010

IRVINE, Calif., Feb. 10 /PRNewswire/ -- Avrio Biopharmaceuticals, LLC, a wholly-owned subsidiary of Irvine Pharmaceutical Services, Inc., received approval to manufacture and ship pharmaceutical products by the California Department of Public Health, Food and Drug Branch (Cal FDB), completing the organization's portfolio of product development services in support of its pharmaceutical, biopharmaceutical, and medical device clients.  

Avrio's newly built, 20,000 square foot, state-of-the-art, aseptic fill-and-finish facility includes three aseptic suites and five production suites with each suite having its own dedicated air handling system. With great confidence in the newly built infrastructure, strategic manufacturing-process flow, state-of-the-art equipment, and experienced staff, Avrio boasts its level of quality by offering clients live video viewing of production (along with on-site viewing access). In addition to a production area designed to provide clients flexibility and scalability, Avrio also includes laboratory space for quality control, microbiology, formulation, and a pilot suite. Furthermore, Avrio's affiliate, Irvine Pharmaceutical Services, Inc., located just across the street, has over 65,000 square feet of laboratory space which provides complete cGMP analytical CMC support.

With multiple manufacturing contracts in place and a number of agreements underway, Avrio has continued to value the core principles of its affiliate, Irvine Pharmaceutical Services.  "For the past 22 years we have been dedicated to continual improvement of our systems and infrastructures in order to better serve the needs of our clients," said Assad J. Kazeminy, CEO and Founder of Irvine Pharmaceutical Services. "With the addition of Avrio, we can now support our clients from start to finish via a seamless partnership."

You can learn more about Avrio and the executive team at the upcoming 2010 PDA Annual Meeting, booth 714.

About Avrio Biopharmaceuticals, LLC

Avrio Biopharma, an affiliate of Irvine Pharmaceutical Services, is a premier contract development and manufacturing organization providing support to the pharmaceutical, biopharmaceutical, and medical device industries. Avrio, along with its Irvine affiliate, offers full cGMP product development support, specializing in preformulation/formulation, analytical development, process validation, scale-up studies, packaging and labeling, stability storage and complete analytical CMC testing. Learn more at www.avriobiopharma.com or call 866-98-AVRIO (866-982-8746).

SOURCE Avrio Biopharmaceuticals, LLC

RELATED LINKS
http://www.avriobiopharma.com
http://www.irvinepharma.com

'/>"/>

SOURCE Avrio Biopharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter
2. InteKrin Therapeutics Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
3. Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
4. Lillys Online, Interactive Health Education Program Receives Two Web Awards
5. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
6. INNOPHARMA Receives First FDA Approval
7. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
8. Mylan Receives Approval for Generic Version of GoLytely(R)
9. Merck Receives European Approval for ELONVA(R) (corifollitropin alfa injection), a New Fertility Treatment
10. Notal Visions ForeseeHome(TM) AMD Monitor Receives FDA Clearance
11. Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ( ... diversifiée innovante, est ravie d,annoncer les excellents résultats semestriels ... période précédente correspondante. Une présentation complète « Résultats et mise ... consultée ici . Faits marquants ... 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
Breaking Medicine Technology:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, ... their Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, ... generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... ... 23, 2017 , ... EBSCO Information Services (EBSCO) ... for Health and Care Excellence (NICE) framework. The agreement allows purchasers from ... to search, order and purchase medical and healthcare-related content through GOBI ®, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
Breaking Medicine News(10 mins):